LegalizeCommission Implementing Regulation (EU) 2023/1808 of 21 September 2023 setting out the template for the provision of information on prevention, preparedness and response planning in relation to serious cross-border threats to health in accordance with Regulation (EU) 2022/2371 of the European Parliament and of the Council
This is the act as published. Later amendments are not folded into the text below: each one is a separate act in this repository and an entry in this law's history.
| Question | Question | Question | Question | Question | Question | Indicator | |
| A.7.1 | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) provide for foresight assessment of the potential impact of a health emergency on continuity of healthcare services? (yes/no/other) — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) provide for foresight assessment of the potential impact of a health emergency on continuity of healthcare services? (yes/no/other) — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) provide for foresight assessment of the potential impact of a health emergency on continuity of healthcare services? (yes/no/other) — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) provide for foresight assessment of the potential impact of a health emergency on continuity of healthcare services? (yes/no/other) — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) provide for foresight assessment of the potential impact of a health emergency on continuity of healthcare services? (yes/no/other) — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) provide for foresight assessment of the potential impact of a health emergency on continuity of healthcare services? (yes/no/other) — If other, please describe: | N/A |
| A.7.2 | In the case of a public health emergency where there is an increase in demand for healthcare provision and potential decrease in healthcare staff, please indicate your Member State’s corresponding level: | In the case of a public health emergency where there is an increase in demand for healthcare provision and potential decrease in healthcare staff, please indicate your Member State’s corresponding level: | In the case of a public health emergency where there is an increase in demand for healthcare provision and potential decrease in healthcare staff, please indicate your Member State’s corresponding level: | In the case of a public health emergency where there is an increase in demand for healthcare provision and potential decrease in healthcare staff, please indicate your Member State’s corresponding level: | In the case of a public health emergency where there is an increase in demand for healthcare provision and potential decrease in healthcare staff, please indicate your Member State’s corresponding level: | In the case of a public health emergency where there is an increase in demand for healthcare provision and potential decrease in healthcare staff, please indicate your Member State’s corresponding level: | Indicator 1-5 or N/A |
| A.7.2 | Hospital services | Outpatient primary care services | Laboratory services (outside of hospitals) | Other public health services | Indicator 1-5 or N/A | ||
| A.7.2 | N/A | Member State cannot answer the question at central state level | Indicator 1-5 or N/A | ||||
| A.7.2 | Level 1 | Your Member State does not have a dedicated operational plan for continuity of healthcare service | Indicator 1-5 or N/A | ||||
| A.7.2 | Level 2 | Your Member State has a dedicated operational plan for continuity of healthcare service | Indicator 1-5 or N/A | ||||
| A.7.2 | Level 3 | Your Member State has a dedicated operational plan for continuity of healthcare service, but it has not been tested in the last 3 years | Indicator 1-5 or N/A | ||||
| A.7.2 | Level 4 | Your Member State has a dedicated operational plan for continuity of healthcare service, and it has been tested in the last 3 years | Indicator 1-5 or N/A | ||||
| A.7.2 | Level 5 | As per level 4 and, in addition, recommendations from the testing have been implemented and the operational plan has been reviewed and revised | Indicator 1-5 or N/A | ||||
| A.7.2 | — If level 2 or above, please advise if this includes a mechanism for prioritisation/flexibility of health service provision to ensure sufficient continuity of care? (yes/no/other) — If yes, is this a permanent or an ad hoc mechanism? — If yes, has the mechanism been tested in the last 3 years and is there a provision for regular testing? — If no, please describe why: — If other, please describe: — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not please explain | — If level 2 or above, please advise if this includes a mechanism for prioritisation/flexibility of health service provision to ensure sufficient continuity of care? (yes/no/other) — If yes, is this a permanent or an ad hoc mechanism? — If yes, has the mechanism been tested in the last 3 years and is there a provision for regular testing? — If no, please describe why: — If other, please describe: — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not please explain | — If level 2 or above, please advise if this includes a mechanism for prioritisation/flexibility of health service provision to ensure sufficient continuity of care? (yes/no/other) — If yes, is this a permanent or an ad hoc mechanism? — If yes, has the mechanism been tested in the last 3 years and is there a provision for regular testing? — If no, please describe why: — If other, please describe: — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not please explain | — If level 2 or above, please advise if this includes a mechanism for prioritisation/flexibility of health service provision to ensure sufficient continuity of care? (yes/no/other) — If yes, is this a permanent or an ad hoc mechanism? — If yes, has the mechanism been tested in the last 3 years and is there a provision for regular testing? — If no, please describe why: — If other, please describe: — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not please explain | — If level 2 or above, please advise if this includes a mechanism for prioritisation/flexibility of health service provision to ensure sufficient continuity of care? (yes/no/other) — If yes, is this a permanent or an ad hoc mechanism? — If yes, has the mechanism been tested in the last 3 years and is there a provision for regular testing? — If no, please describe why: — If other, please describe: — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not please explain | — If level 2 or above, please advise if this includes a mechanism for prioritisation/flexibility of health service provision to ensure sufficient continuity of care? (yes/no/other) — If yes, is this a permanent or an ad hoc mechanism? — If yes, has the mechanism been tested in the last 3 years and is there a provision for regular testing? — If no, please describe why: — If other, please describe: — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not please explain | Indicator 1-5 or N/A |
| A.7.3 | Please advise if your Member State ensures interdisciplinary crisis management coordination between all actors of the health care system (e.g., hospital services, rescue services, other public health services, outpatient primary care services, pharmacies, laboratory services, nursing/rehabilitation services)? (yes/no/other) — If other, please describe: | Please advise if your Member State ensures interdisciplinary crisis management coordination between all actors of the health care system (e.g., hospital services, rescue services, other public health services, outpatient primary care services, pharmacies, laboratory services, nursing/rehabilitation services)? (yes/no/other) — If other, please describe: | Please advise if your Member State ensures interdisciplinary crisis management coordination between all actors of the health care system (e.g., hospital services, rescue services, other public health services, outpatient primary care services, pharmacies, laboratory services, nursing/rehabilitation services)? (yes/no/other) — If other, please describe: | Please advise if your Member State ensures interdisciplinary crisis management coordination between all actors of the health care system (e.g., hospital services, rescue services, other public health services, outpatient primary care services, pharmacies, laboratory services, nursing/rehabilitation services)? (yes/no/other) — If other, please describe: | Please advise if your Member State ensures interdisciplinary crisis management coordination between all actors of the health care system (e.g., hospital services, rescue services, other public health services, outpatient primary care services, pharmacies, laboratory services, nursing/rehabilitation services)? (yes/no/other) — If other, please describe: | Please advise if your Member State ensures interdisciplinary crisis management coordination between all actors of the health care system (e.g., hospital services, rescue services, other public health services, outpatient primary care services, pharmacies, laboratory services, nursing/rehabilitation services)? (yes/no/other) — If other, please describe: | N/A |
| A.7.4 | Regarding your Member State’s business continuity plans for healthcare providers in case of a disruptive event, please indicate your country’s corresponding level: | Regarding your Member State’s business continuity plans for healthcare providers in case of a disruptive event, please indicate your country’s corresponding level: | Regarding your Member State’s business continuity plans for healthcare providers in case of a disruptive event, please indicate your country’s corresponding level: | Regarding your Member State’s business continuity plans for healthcare providers in case of a disruptive event, please indicate your country’s corresponding level: | Regarding your Member State’s business continuity plans for healthcare providers in case of a disruptive event, please indicate your country’s corresponding level: | Regarding your Member State’s business continuity plans for healthcare providers in case of a disruptive event, please indicate your country’s corresponding level: | Indicator 1-5 or N/A |
| A.7.4 | Level | ||||||
| A.7.4 | Member State cannot answer the question [at central state level | Member State cannot answer the question [at central state level | Member State cannot answer the question [at central state level | Member State cannot answer the question [at central state level | Member State cannot answer the question [at central state level | N/A | |
| A.7.4 | There is/are no national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | There is/are no national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | There is/are no national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | There is/are no national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | There is/are no national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | 1 | |
| A.7.4 | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services | 2 | |
| A.7.4 | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years | 3 | |
| A.7.4 | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years using a multi-sectoral approach | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years using a multi-sectoral approach | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years using a multi-sectoral approach | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years using a multi-sectoral approach | There is/are national guidance/recommendations for business continuity plans (or equivalents such as contingency plans) to ensure the continuity of healthcare services and guidance/recommendations have been reviewed and revised in the past 3 years using a multi-sectoral approach | 4 | |
| A.7.4 | As per level 4 and, in addition, all healthcare services implement the national guidance/recommendations for business continuity plans | As per level 4 and, in addition, all healthcare services implement the national guidance/recommendations for business continuity plans | As per level 4 and, in addition, all healthcare services implement the national guidance/recommendations for business continuity plans | As per level 4 and, in addition, all healthcare services implement the national guidance/recommendations for business continuity plans | As per level 4 and, in addition, all healthcare services implement the national guidance/recommendations for business continuity plans | 5 | |
| A.7.4 | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If no, please explain | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If no, please explain | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If no, please explain | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If no, please explain | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If no, please explain | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If no, please explain | |
| A.7.5 | Please advise if your Member State requires hospitals to have a hospital alert and response plan or equivalent document(s)6 in order to be prepared for public health emergencies that may affect a hospital’s capacity and function? (yes/no/other) — If yes, please advise if the plans include instructions on how to sustain patient care in the event of a shortage (medical personnel, medical stockpile, treatment facilities) or a technical breakdown (e.g., energy, water, IT): — If yes, please advise if these plans or equivalent document(s) are tested on a regular basis: — If other, please describe: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain: | Please advise if your Member State requires hospitals to have a hospital alert and response plan or equivalent document(s)6 in order to be prepared for public health emergencies that may affect a hospital’s capacity and function? (yes/no/other) — If yes, please advise if the plans include instructions on how to sustain patient care in the event of a shortage (medical personnel, medical stockpile, treatment facilities) or a technical breakdown (e.g., energy, water, IT): — If yes, please advise if these plans or equivalent document(s) are tested on a regular basis: — If other, please describe: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain: | Please advise if your Member State requires hospitals to have a hospital alert and response plan or equivalent document(s)6 in order to be prepared for public health emergencies that may affect a hospital’s capacity and function? (yes/no/other) — If yes, please advise if the plans include instructions on how to sustain patient care in the event of a shortage (medical personnel, medical stockpile, treatment facilities) or a technical breakdown (e.g., energy, water, IT): — If yes, please advise if these plans or equivalent document(s) are tested on a regular basis: — If other, please describe: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain: | Please advise if your Member State requires hospitals to have a hospital alert and response plan or equivalent document(s)6 in order to be prepared for public health emergencies that may affect a hospital’s capacity and function? (yes/no/other) — If yes, please advise if the plans include instructions on how to sustain patient care in the event of a shortage (medical personnel, medical stockpile, treatment facilities) or a technical breakdown (e.g., energy, water, IT): — If yes, please advise if these plans or equivalent document(s) are tested on a regular basis: — If other, please describe: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain: | Please advise if your Member State requires hospitals to have a hospital alert and response plan or equivalent document(s)6 in order to be prepared for public health emergencies that may affect a hospital’s capacity and function? (yes/no/other) — If yes, please advise if the plans include instructions on how to sustain patient care in the event of a shortage (medical personnel, medical stockpile, treatment facilities) or a technical breakdown (e.g., energy, water, IT): — If yes, please advise if these plans or equivalent document(s) are tested on a regular basis: — If other, please describe: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain: | Please advise if your Member State requires hospitals to have a hospital alert and response plan or equivalent document(s)6 in order to be prepared for public health emergencies that may affect a hospital’s capacity and function? (yes/no/other) — If yes, please advise if the plans include instructions on how to sustain patient care in the event of a shortage (medical personnel, medical stockpile, treatment facilities) or a technical breakdown (e.g., energy, water, IT): — If yes, please advise if these plans or equivalent document(s) are tested on a regular basis: — If other, please describe: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain: | N/A |
| A.7.6 | Does your Member State have the capacity to map immediately available health services in the case of a public health emergency? (yes/no/other) — If other, please describe: | Does your Member State have the capacity to map immediately available health services in the case of a public health emergency? (yes/no/other) — If other, please describe: | Does your Member State have the capacity to map immediately available health services in the case of a public health emergency? (yes/no/other) — If other, please describe: | Does your Member State have the capacity to map immediately available health services in the case of a public health emergency? (yes/no/other) — If other, please describe: | Does your Member State have the capacity to map immediately available health services in the case of a public health emergency? (yes/no/other) — If other, please describe: | Does your Member State have the capacity to map immediately available health services in the case of a public health emergency? (yes/no/other) — If other, please describe: | N/A |
| A.7.7 | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) include agreements and/or provisions for the medical transfer of patients and/or mobile medical teams with other countries? (yes/no/other) — If yes, please list countries involved: — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) include agreements and/or provisions for the medical transfer of patients and/or mobile medical teams with other countries? (yes/no/other) — If yes, please list countries involved: — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) include agreements and/or provisions for the medical transfer of patients and/or mobile medical teams with other countries? (yes/no/other) — If yes, please list countries involved: — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) include agreements and/or provisions for the medical transfer of patients and/or mobile medical teams with other countries? (yes/no/other) — If yes, please list countries involved: — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) include agreements and/or provisions for the medical transfer of patients and/or mobile medical teams with other countries? (yes/no/other) — If yes, please list countries involved: — If other, please describe: | Does your Member State’s prevention, preparedness and response plan or equivalent document(s) include agreements and/or provisions for the medical transfer of patients and/or mobile medical teams with other countries? (yes/no/other) — If yes, please list countries involved: — If other, please describe: | N/A |
8. Risk communication
| Question | Question | Indicator | |
| A.8.1 | Regarding risk communication, please indicate your country’s corresponding level: | Regarding risk communication, please indicate your country’s corresponding level: | Indicator 1-5 or N/A |
| A.8.1 | level | Indicator 1-5 or N/A | |
| A.8.1 | Member State cannot answer the question at central state level | N/A | Indicator 1-5 or N/A |
| A.8.1 | There is no separate national risk communication plan or risk communication section as part of a preparedness and response plan or equivalent document(s) is not in place and mechanisms for public communication are on an ad-hoc basis and only includes conventional media focus | 1 | Indicator 1-5 or N/A |
| A.8.1 | A separate national risk communication plan or section in a preparedness and response plan or equivalent document(s) is being developed and mechanisms for public communication are on an ad-hoc basis and includes conventional media with minimal online and social media focus | 2 | Indicator 1-5 or N/A |
| A.8.1 | National risk communication is in place as a defined section within a preparedness and response plan or equivalent document(s) and includes conventional media and online and social media focus. In addition, there is analysis of target audiences and preferred communication channels to inform risk communication interventions | 3 | Indicator 1-5 or N/A |
| A.8.1 | A separate, dedicated national risk communication plan is in place and includes conventional media and online and social media focus. In addition, there is analysis of target audiences and preferred communication channels to inform risk communication interventions. Moreover, there is proactive outreach through a variety of channels (e.g. hotline, complaint systems, social listening), online and offline media are monitored daily for feedback and insights and data are used to adjust and improve risk communication strategies | 4 | Indicator 1-5 or N/A |
| A.8.1 | As per level 4 and, in addition, the national risk communication plan has been tested in the last 3 years | 5 | Indicator 1-5 or N/A |
| A.8.1 | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain: | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain: | Indicator 1-5 or N/A |
| A.8.2 | Does your Member State’s risk communication plan include a dedicated step to coordinate in liaison with the HSC the risk and crisis communication related to a serious cross-border threat to health? (yes/no/other) — If other, please describe: | Does your Member State’s risk communication plan include a dedicated step to coordinate in liaison with the HSC the risk and crisis communication related to a serious cross-border threat to health? (yes/no/other) — If other, please describe: | N/A |
9. Points of entry (PoEs) and border health
| Question | Question | Question | Question | Question | Indicator | |
| A.9.1 | Regarding your Member State’s nationally designated POEs public health emergency contingency plans, please indicate your Member State’s corresponding level: | Regarding your Member State’s nationally designated POEs public health emergency contingency plans, please indicate your Member State’s corresponding level: | Regarding your Member State’s nationally designated POEs public health emergency contingency plans, please indicate your Member State’s corresponding level: | Regarding your Member State’s nationally designated POEs public health emergency contingency plans, please indicate your Member State’s corresponding level: | Regarding your Member State’s nationally designated POEs public health emergency contingency plans, please indicate your Member State’s corresponding level: | Indicator 1-5 |
| A.9.1 | Ports | Airports | Ground Crossings | Indicator 1-5 | ||
| A.9.1 | Level 1 | The nationally designated POEs’ public health emergency contingency plan has no operational instruments to facilitate sharing of travel related health data/information and reporting to the national level | Indicator 1-5 | |||
| A.9.1 | Level 2 | The nationally designated POEs’ public health emergency contingency plan has operational instruments to facilitate sharing of travel related health data/information and reporting to the national level | Indicator 1-5 | |||
| A.9.1 | Level 3 | The nationally designated POEs’ public health emergency contingency plan has operational instruments to facilitate sharing of travel related health data/information and reporting to the national level and this has been tested in the last 3 years | Indicator 1-5 | |||
| A.9.1 | Level 4 | The nationally designated POEs’ public health emergency contingency plan has operational instruments to facilitate sharing of travel related health data/information and reporting to the national level and this has been tested in the last 3 years. In addition, the national level also has operational instruments to then facilitate the sharing of this information to other national sectors7 and third parties e.g. WHO and Early Warning Response System (EWRS) | Indicator 1-5 | |||
| A.9.1 | Level 5 | As per level 4 and, in addition, this has been tested in the last 3 years | Indicator 1-5 | |||
| A.9.1 | — Additional comments: | — Additional comments: | — Additional comments: | — Additional comments: | — Additional comments: | Indicator 1-5 |
| A.9.2 | Regarding the implementation and evaluation of international travel-related measures please advise: — If the implementation of international-travel related measures has been tested in at least one nationally designated POE in the last 3 years (yes/no/other) — If other, please describe: — If there is a dedicated step to discuss with the HSC prior to implementation of international travel related measures? (yes/no/other) — If other, please describe: | Regarding the implementation and evaluation of international travel-related measures please advise: — If the implementation of international-travel related measures has been tested in at least one nationally designated POE in the last 3 years (yes/no/other) — If other, please describe: — If there is a dedicated step to discuss with the HSC prior to implementation of international travel related measures? (yes/no/other) — If other, please describe: | Regarding the implementation and evaluation of international travel-related measures please advise: — If the implementation of international-travel related measures has been tested in at least one nationally designated POE in the last 3 years (yes/no/other) — If other, please describe: — If there is a dedicated step to discuss with the HSC prior to implementation of international travel related measures? (yes/no/other) — If other, please describe: | Regarding the implementation and evaluation of international travel-related measures please advise: — If the implementation of international-travel related measures has been tested in at least one nationally designated POE in the last 3 years (yes/no/other) — If other, please describe: — If there is a dedicated step to discuss with the HSC prior to implementation of international travel related measures? (yes/no/other) — If other, please describe: | Regarding the implementation and evaluation of international travel-related measures please advise: — If the implementation of international-travel related measures has been tested in at least one nationally designated POE in the last 3 years (yes/no/other) — If other, please describe: — If there is a dedicated step to discuss with the HSC prior to implementation of international travel related measures? (yes/no/other) — If other, please describe: | N/A |
10. Zoonotic diseases and threats of environmental origin, including those due to the climate
| Question | Question | Indicator | |
| A.10.1 | Regarding your country’s implementation of One Health as referred to in Article 3(7) of the Regulation (EU) 2022/2371, please indicate your Member State’ s corresponding level: | Regarding your country’s implementation of One Health as referred to in Article 3(7) of the Regulation (EU) 2022/2371, please indicate your Member State’ s corresponding level: | Indicator 1-5 or N/A |
| A.10.1 | Level | Indicator 1-5 or N/A | |
| A.10.1 | Member State cannot answer question as Member State does not have a prevention, preparedness and response plan or equivalent document(s) | N/A | Indicator 1-5 or N/A |
| A.10.1 | There is no One Health approach in the preparedness and response plan or equivalent document(s) | 1 | Indicator 1-5 or N/A |
| A.10.1 | A One Health approach in the preparedness and response plan or equivalent document(s) is being developed but coordination of surveillance between animal health, public health, and environmental sectors and mechanisms for information sharing have not been established | 2 | Indicator 1-5 or N/A |
| A.10.1 | A One Health approach in the preparedness and response plan or equivalent document(s) is in place and coordination of surveillance between animal health, public health, and environmental sectors and mechanisms for information sharing has been established | 3 | Indicator 1-5 or N/A |
| A.10.1 | A One Health approach in the preparedness and response plan or equivalent document(s) is in place and coordination of surveillance between animal health, public health, and environmental sectors and mechanisms for information sharing has been established. In addition, this has been tested in the last 3 years | 4 | Indicator 1-5 or N/A |
| A.10.1 | As per level 4 and, in addition, its implementation is monitored and revised on a regular basis | 5 | Indicator 1-5 or N/A |
| A.10.1 | — Additional comments: — If at level 2 or above: — please advise if there is in the preparedness and response plan or equivalent document(s), coordination of surveillance between two out of the three sectors (animal health, public health, and environmental) and mechanisms for information sharing? (yes/no/other) — If yes, please indicate the sectors involved: — If other, please describe: — please indicate if you have developed any joint training programmes for One Health professionals (animal health, public health and environmental sectors) on zoonoses prevention, detection, and response? (yes/no/other) — If other, please describe: — please indicate if you have developed a guideline on the procedures to follow for the public on finding sick and/or dead wild birds and other animals? (yes/no/other) — If other, please describe: — please advise if there is a list of prioritised zoonotic diseases for surveillance purposes? (yes/no/other) — If yes, please list the prioritised zoonotic disease: — If other, please describe: | — Additional comments: — If at level 2 or above: — please advise if there is in the preparedness and response plan or equivalent document(s), coordination of surveillance between two out of the three sectors (animal health, public health, and environmental) and mechanisms for information sharing? (yes/no/other) — If yes, please indicate the sectors involved: — If other, please describe: — please indicate if you have developed any joint training programmes for One Health professionals (animal health, public health and environmental sectors) on zoonoses prevention, detection, and response? (yes/no/other) — If other, please describe: — please indicate if you have developed a guideline on the procedures to follow for the public on finding sick and/or dead wild birds and other animals? (yes/no/other) — If other, please describe: — please advise if there is a list of prioritised zoonotic diseases for surveillance purposes? (yes/no/other) — If yes, please list the prioritised zoonotic disease: — If other, please describe: | Indicator 1-5 or N/A |
| A.10.2 | — Does your Member States integrate provisions about the actual or projected effects of climate change on zoonotic diseases (yes/no/other) If yes, please elaborate on the potential effects and any dedicated provisions for health preparedness and response If other, please describe: | — Does your Member States integrate provisions about the actual or projected effects of climate change on zoonotic diseases (yes/no/other) If yes, please elaborate on the potential effects and any dedicated provisions for health preparedness and response If other, please describe: | N/A |
| A.10.3 | — Does your Member State integrate provisions about the actual or projected impacts of extreme weather events (like heatwaves, floods or – indirectly – wildfires) on public health (yes/no/other) If yes, please elaborate on the potential impacts and any dedicated provisions for health preparedness and response: If other, please describe: | — Does your Member State integrate provisions about the actual or projected impacts of extreme weather events (like heatwaves, floods or – indirectly – wildfires) on public health (yes/no/other) If yes, please elaborate on the potential impacts and any dedicated provisions for health preparedness and response: If other, please describe: |
11. Chemical events
| Question | Question | Indicator | |
| A.11.1 | Regarding the management of a health threat from chemical origin, please indicate your country’s corresponding level: | Regarding the management of a health threat from chemical origin, please indicate your country’s corresponding level: | Indicator 1-5 or N/A |
| A.11.1 | Level | Indicator 1-5 or N/A | |
| A.11.1 | Member State cannot answer the question at central state level | N/A | Indicator 1-5 or N/A |
| A.11.1 | There is no separate chemical preparedness and response plan or equivalent document(s), nor is it included in the preparedness and response plan or equivalent document(s) | 1 | Indicator 1-5 or N/A |
| A.11.1 | There is a chemical preparedness and response plan or equivalent document(s) and/or it is included in the preparedness and response plan or equivalent document(s) | 2 | Indicator 1-5 or N/A |
| A.11.1 | The chemical preparedness and response plan or equivalent document(s) is in place and roles and responsibilities as well as major hazard sites are considered and identified | 3 | Indicator 1-5 or N/A |
| A.11.1 | The chemical preparedness and response plan or equivalent document(s) is in place and roles and responsibilities as well as major hazard sites are considered and identified. In addition, the chemical response plan or chapter in the preparedness and response plan or equivalent document(s) has been tested through a simulation exercise in the last 3 years | 4 | Indicator 1-5 or N/A |
| A.11.1 | As per level 4 and, in addition, recommendations from the test(s) have been implemented and corresponding plans reviewed and revised | 5 | Indicator 1-5 or N/A |
| A.11.1 | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain | — Additional comments: Your Member State cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please advise if national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please explain | Indicator 1-5 or N/A |
| A.11.2 | Does your Member State have procedures for a health risk assessment in case of a health threat from chemical origin? (yes/no/other) — If yes, please describe: — If no, please describe: — If other, please describe: | Does your Member State have procedures for a health risk assessment in case of a health threat from chemical origin? (yes/no/other) — If yes, please describe: — If no, please describe: — If other, please describe: | N/A |
| A.11.3 | Does your Member State have available guidelines on: — Surveillance of chemical events and poisoning/intoxication? (yes/no/other) — If yes, please describe: — If no, please describe: — If other, please describe: — Assessment of chemical events and poisoning/intoxication? (yes/no/other) — If yes, please describe: — If no, please describe: — If other, please describe: — Management of chemical events and poisoning/intoxication? (yes/no/other) — If yes, please describe: — If no, please describe: — If other, please describe: | Does your Member State have available guidelines on: — Surveillance of chemical events and poisoning/intoxication? (yes/no/other) — If yes, please describe: — If no, please describe: — If other, please describe: — Assessment of chemical events and poisoning/intoxication? (yes/no/other) — If yes, please describe: — If no, please describe: — If other, please describe: — Management of chemical events and poisoning/intoxication? (yes/no/other) — If yes, please describe: — If no, please describe: — If other, please describe: | N/A |
B. ADDITIONAL CAPACITIES AS PER REGULATION (EU) 2022/2371
12. Antimicrobial resistance (AMR) and Healthcare associated infections (HAIs)
AMR
| Question | Question | Indicator | |
| B.12.1 | National One Health Action Plans on AMR In order to avoid duplication of efforts, the Commission and the European Center For Disease Prevention and Control (ECDC) will be relying on inputs made to WHO Tracking Antimicrobial Resistance Country Self- Assessment Survey (TrACSS)8. Thus, national reporting to TrACSS will be considered as part of the assessment under Article 8 of Regulation (EU) 2022/2371 Please upload in pdf format your Member State’s most recent TrACSS submission to WHO. Regarding the national action plan (NAP) on AMR, have there been any updates since your country’s last reporting to TrACSS? — No — Yes (please detail in the open text) | National One Health Action Plans on AMR In order to avoid duplication of efforts, the Commission and the European Center For Disease Prevention and Control (ECDC) will be relying on inputs made to WHO Tracking Antimicrobial Resistance Country Self- Assessment Survey (TrACSS)8. Thus, national reporting to TrACSS will be considered as part of the assessment under Article 8 of Regulation (EU) 2022/2371 Please upload in pdf format your Member State’s most recent TrACSS submission to WHO. Regarding the national action plan (NAP) on AMR, have there been any updates since your country’s last reporting to TrACSS? — No — Yes (please detail in the open text) | N/A |
| B.12.2 | Resources What resources are allocated to the implementation of the NAP on AMR? | Resources What resources are allocated to the implementation of the NAP on AMR? | N/A |
| B.12.2 | Level | N/A | |
| B.12.2 | No or very few resources (budget and human resources) are available for the implementation of the NAP. | 1 | N/A |
| B.12.2 | No specific resources are available, and implementation is entrusted to the resources (budget and human resources) of national/regional stakeholders (e.g. relevant competent authorities responsible for health, agriculture, environment, etc.) involved in the implementation of the NAP | 2 | N/A |
| B.12.2 | Non-earmarked funding can be accessed for AMR activities from national/regional funds and can be used for implementation of the NAP | 3 | N/A |
| B.12.2 | Specific earmarked funding for AMR activities is available from national/regional funds and is used for implementation of the NAP | 4 | N/A |
| B.12.2 | Implementation of the NAP is fully costed and funded through dedicated budget lines from national/regional funds. | 5 | N/A |
| B.12.2 | — Additional comments: | — Additional comments: | N/A |
| B.12.3 | Monitoring and evaluation of progress Does your Member State have national indicators or targets to measure national progress on AMR (including antimicrobial consumption/use) and/or HAIs? Please, provide a description of the indicators/targets or a hyperlink to where they can be found in the comments section. | Monitoring and evaluation of progress Does your Member State have national indicators or targets to measure national progress on AMR (including antimicrobial consumption/use) and/or HAIs? Please, provide a description of the indicators/targets or a hyperlink to where they can be found in the comments section. | Indicator 1-5 |
| B.12.3 | Level | Indicator 1-5 | |
| B.12.3 | No, there are neither national indicators, nor national targets to measure progress on AMR (including antimicrobial consumption/use) and/or HAIs in the country | 1 | Indicator 1-5 |
| B.12.3 | There are plans to set up national indicators and/or national targets, and these will be in place in the near future | 2 | Indicator 1-5 |
| B.12.3 | There are national indicators, similar to the globally available indicators (e.g. Sustainable Development Goals and WHO, etc.), but without targets | 3 | Indicator 1-5 |
| B.12.3 | Yes, there are national indicators that cover AMR (including antimicrobial consumption/use) and/or HAIs with concrete national targets to be reached by a certain timeframe, and progress is reviewed regularly but this is not linked to the objectives of the NAP on AMR | 4 | Indicator 1-5 |
| B.12.3 | Yes, there are national indicators and national targets that cover both AMR (including antimicrobial consumption/use) and HAIs, which are linked to the NAP on AMR, and progress is reviewed regularly | 5 | Indicator 1-5 |
| B.12.3 | — Additional comments: | — Additional comments: | Indicator 1-5 |
| B.12.4 | Main challenges Currently, what are the biggest challenges that your Member State faces in addressing AMR? Please choose three challenges, then rank them from 3 – the most important to 1 – the least important): | Main challenges Currently, what are the biggest challenges that your Member State faces in addressing AMR? Please choose three challenges, then rank them from 3 – the most important to 1 – the least important): | N/A |
| B.12.4 | Implementation of prevention and control measures in routine practice | N/A | |
| B.12.4 | Budget limitations | N/A | |
| B.12.4 | Ensuring One-health coordination across the different sectors | N/A | |
| B.12.4 | Absence of or insufficient legal framework | N/A | |
| B.12.4 | Lack of human resources | N/A | |
| B.12.4 | Infrastructure limitations (e.g. lack of single rooms, old hospital buildings, etc.) | N/A | |
| B.12.4 | Insufficient awareness among stakeholders such as healthcare professionals, e.g. doctors, nurses, pharmacists, etc., animal keepers and farmers and the general public | N/A | |
| B.12.4 | Limited access to certain antimicrobials, e.g. narrow-spectrum antibiotics and novel antimicrobials | N/A | |
| B.12.4 | — Additional comments: | — Additional comments: | N/A |
| B.12.5 | Prevention of priority multidrug-resistant organisms (MDROs) Regarding the prevention of multidrug resistant organism, please indicate your Member State’s level below. Note: the below levels have been adapted based on the wording of the Joint External Evaluation (JEE)9, question P4.3 referring to the prevention of multidrug resistant organism. The MDROs considered under this indicator are listed below, as they are considered critical at Union level. If a Member State considers that its replies cannot cover all MDROs, this can be specified in the comments section below. | Prevention of priority multidrug-resistant organisms (MDROs) Regarding the prevention of multidrug resistant organism, please indicate your Member State’s level below. Note: the below levels have been adapted based on the wording of the Joint External Evaluation (JEE)9, question P4.3 referring to the prevention of multidrug resistant organism. The MDROs considered under this indicator are listed below, as they are considered critical at Union level. If a Member State considers that its replies cannot cover all MDROs, this can be specified in the comments section below. | Indicator 1-5 |
| B.12.5 | Level | Indicator 1-5 | |
| B.12.5 | These MDROs (phenotypes and genotypes) have not been identified as priority by national authorities, and they are not detected | 1 | Indicator 1-5 |
| B.12.5 | National strategy or guidance for MDRO containment exists and includes colonization screening for priority MDROs (phenotypes and genotypes) that have been identified by national authorities. Some health facilities can detect priority MDROs based on laboratory data. | 2 | Indicator 1-5 |
| B.12.5 | Selected health facilities have access to MDRO phenotype confirmation. Facilities notify national levels when priority MDROs are detected | 3 | Indicator 1-5 |
| B.12.5 | All health facilities have access to MDRO phenotype confirmation. Facilities notify national levels when priority MDROs are detected in a timely manner. Responses are tracked and supported at the national level | 4 | Indicator 1-5 |
| B.12.5 | Functional system is in place to rapidly communicate and track the detection, confirmation and notification of novel or priority MDROs within hospitals and to national levels. All hospitals are able to launch response activities to priority MDROs in a timely manner. Facilities regularly communicate pertinent MDRO data to local referral networks to inform prevention/containment efforts | 5 | Indicator 1-5 |
| B.12.5 | — Additional comments: | — Additional comments: | Indicator 1-5 |
| B.12.6 | Priority MDROs in hospitals and cross-border patient transfers Regarding national activities related to screening patients for MDRO carriage at hospital admission, as a means to reduce the spread of priority MDROs among hospitals, please indicate your Member States’ s corresponding level below. Note: the MDROs considered under the indicator are listed below, as they are considered critical at Union level. If a Member State considers that its replies cannot cover all MDROs, this can be specified in the comments section below. | Priority MDROs in hospitals and cross-border patient transfers Regarding national activities related to screening patients for MDRO carriage at hospital admission, as a means to reduce the spread of priority MDROs among hospitals, please indicate your Member States’ s corresponding level below. Note: the MDROs considered under the indicator are listed below, as they are considered critical at Union level. If a Member State considers that its replies cannot cover all MDROs, this can be specified in the comments section below. | Indicator 1-5 |
| B.12.6 | Level | Indicator 1-5 | |
| B.12.6 | There are no national procedures and protocols in place for screening patients for MDRO carriage at hospital admission | 1 | Indicator 1-5 |
| B.12.6 | There are national procedures and protocols in place for screening for MDRO carriage only for patients being directly transferred from a hospital in another country | 2 | Indicator 1-5 |
| B.12.6 | There are national procedures and protocols in place for screening for MDRO carriage only for patients being directly transferred from a hospital in another country or who have recently been hospitalised in another country | 3 | Indicator 1-5 |
| B.12.6 | There are national procedures and protocols in place for screening for MDRO carriage only for patients being directly transferred from a hospital in another country or who have recently been hospitalised in another country, as well as for patients admitted to special wards, such as intensive care units | 4 | Indicator 1-5 |
| B.12.6 | There are national procedures and protocols in place for screening for MDRO carriage for all patients, at hospital admission | 5 | Indicator 1-5 |
| B.12.6 | — Additional comments: Do you have national requirements to communicate on the infection status of a patient (i.e. information on infection by/carriage of a communicable microorganism, in particular priority MDROs, when referred from one hospital (or healthcare facility) to another? (yes/no/other) — Yes, in case of cross-border transfer as well as transfer to a hospital (or healthcare facility) within the country — Yes, only in case of cross-border transfer — No (please explain why) — If other, please describe: | Indicator 1-5 | |
| B.12.7 | Antimicrobial stewardship/prudent use of antimicrobials in primary and secondary care: Regarding the optimal use of antimicrobial medicines in human health, please indicate your Member State’s corresponding level below. Note: the below indicator levels have been adapted based on the wording of the Joint External Evaluation (JEE)10, question P4.4 referring to the optimal use of antimicrobial medicines in human health | Antimicrobial stewardship/prudent use of antimicrobials in primary and secondary care: Regarding the optimal use of antimicrobial medicines in human health, please indicate your Member State’s corresponding level below. Note: the below indicator levels have been adapted based on the wording of the Joint External Evaluation (JEE)10, question P4.4 referring to the optimal use of antimicrobial medicines in human health | Indicator 1-5 |
| B.12.7 | Level | Indicator 1-5 | |
| B.12.7 | No or weak national policy and/or regulations on appropriate use, availability, quality and use of antimicrobials in human health | 1 | Indicator 1-5 |
| B.12.7 | National policy and regulations promoting appropriate antimicrobial use/antimicrobial stewardship activities are developed for the community and health care settings | 2 | Indicator 1-5 |
| B.12.7 | Guidelines for appropriate use of antimicrobials are available and antimicrobial stewardship programmes are established in some health care facilities. The latest WHO “Access, Watch and Reserve” (AWaRe) classification of antibiotics is adopted in the national essential medicines list | 3 | Indicator 1-5 |
| B.12.7 | Guidelines and practices to enable appropriate use of antimicrobials are implemented in health care facilities nationwide. Functioning AMR stewardship programs in all major health care facilities. Monitoring of antibiotic consumption is being performed and based on the latest AWaRe classification of antibiotics | 4 | Indicator 1-5 |
| B.12.7 | Guidelines on optimizing antibiotic use are implemented for all major syndromes and data on use is systematically fed back to prescribers. The AWaRe classification of antibiotics is incorporated into antimicrobial stewardship strategies. Robust national monitoring of antibiotic consumption is being performed | 5 | Indicator 1-5 |
| B.12.7 | — Additional comments: | — Additional comments: | Indicator 1-5 |
| B.12.8 | AMR surveillance Regarding the surveillance of AMR, please indicate your Member State’s corresponding level below. Note: the below indicator levels have been adapted based on the wording of the Joint External Evaluation (JEE)11, question P4.2 referring to the surveillance of AMR | AMR surveillance Regarding the surveillance of AMR, please indicate your Member State’s corresponding level below. Note: the below indicator levels have been adapted based on the wording of the Joint External Evaluation (JEE)11, question P4.2 referring to the surveillance of AMR | Indicator 1-5 |
| B.12.8 | Level | Indicator 1-5 | |
| B.12.8 | No or limited capacity for generating, collating, and reporting data (antibiotic susceptibility testing and accompanying clinical and epidemiological data) | 1 | Indicator 1-5 |
| B.12.8 | AMR data are collated locally for common pathogens in hospitalized and community patients, but data collection may not use a standard approach and lacks national coordination and/or quality management | 2 | Indicator 1-5 |
| B.12.8 | AMR data are collated nationally for common pathogens, but national coordination and standardization are lacking | 3 | Indicator 1-5 |
| B.12.8 | There is a standardized national AMR surveillance system collecting data on common pathogens in hospitalized and community patients, with an established network of surveillance sites, designated national reference laboratory for AMR and a national coordinating centre producing reports on AMR | 4 | Indicator 1-5 |
| B.12.8 | In addition to the above, the national AMR surveillance system’s data is analysed, interpreted and reported together with antimicrobial consumption and/or use data for human health, and analysis of similar data across sectors (human and animal health and agriculture) is attempted | 5 | Indicator 1-5 |
| B.12.8 | — Additional comments: | Indicator 1-5 |
Healthcare associated infections (HAIs)
| Question | Question | Indicator | |
| B.12.9 | Main challenges Currently, what are the biggest challenges that your country faces in addressing healthcare associated infections (HAIs)? Please choose three challenges, then rank them from 3 – the most important to 1- the least important): | Main challenges Currently, what are the biggest challenges that your country faces in addressing healthcare associated infections (HAIs)? Please choose three challenges, then rank them from 3 – the most important to 1- the least important): | N/A |
| B.12.9 | Implementation of prevention and control measures in routine practice | N/A | |
| B.12.9 | Budget limitations | N/A | |
| B.12.9 | Absence of or insufficient legal framework | N/A | |
| B.12.9 | Lack of human resources | N/A | |
| B.12.9 | Infrastructure limitations (e.g. lack of single rooms, old hospital buildings, etc.) | N/A | |
| B.12.9 | Insufficient awareness among healthcare professionals, e.g. doctors, nurses, pharmacists, etc. and the general public | N/A | |
| B.12.9 | Limited access to certain antimicrobials, e.g. narrow-spectrum antibiotics and novel antimicrobials | N/A | |
| B.12.9 | — Additional comments: | — Additional comments: | N/A |
| B.12.10 | HAI surveillance Regarding the surveillance of HAI, please indicate your Member State’s corresponding level below. Note: the below indicator levels have been adapted based on the wording of the Joint External Evaluation (JEE)12, question R4.2 referring to the surveillance of HAI | HAI surveillance Regarding the surveillance of HAI, please indicate your Member State’s corresponding level below. Note: the below indicator levels have been adapted based on the wording of the Joint External Evaluation (JEE)12, question R4.2 referring to the surveillance of HAI | Indicator 1-5 |
| B.12.10 | Level | Indicator 1-5 | |
| B.12.10 | No national HAI surveillance programme or national strategic plan for HAI surveillance, including pathogens that are antimicrobial resistant and/or prone to outbreaks is available or under development | 1 | Indicator 1-5 |
| B.12.10 | A national strategic plan for HAI surveillance (including pathogens that are antimicrobial resistant and/or prone to outbreaks) is available but not implemented | 2 | Indicator 1-5 |
| B.12.10 | A national strategic plan for HAI surveillance (including pathogens that are antimicrobial resistant and/or prone to outbreaks) is available and implemented through a national programme and system for data collection, analysis, and feedback. Selected secondary and tertiary health care facilities are conducting HAI surveillance (as specified above) and provide timely and regular feedback to senior management and health workers | 3 | Indicator 1-5 |
| B.12.10 | A national strategic plan for HAI surveillance (including pathogens that are antimicrobial resistant and/or prone to outbreaks) is available and implemented nationwide in all secondary and tertiary health care facilities through a national system according to the WHO recommendations on Infection Prevention and Control (IPC) core components. Regular reports are available for providing feedback | 4 | Indicator 1-5 |
| B.12.10 | A national strategic plan for HAI surveillance (including pathogens that are antimicrobial resistant and/or prone to outbreaks) are available and implemented nationwide in all secondary and tertiary health care facilities through a national programme and system according to the WHO recommendations on IPC core components. Data are shared and being used continuously and in a timely manner to inform prevention efforts. The quality and impact of the system are regularly evaluated, and improvement actions are taken accordingly | 5 | Indicator 1-5 |
| B.12.10 | — Additional comments: | — Additional comments: | Indicator 1-5 |
13. Union level coordination and support functions
Reading this document does not replace reading the official text published in the Official Journal of the European Union. We assume no responsibility for any inaccuracies arising from the conversion of the original to this format.
This text is published under EUR-Lex's own terms of reuse, not a Legalize or public-domain licence.
EUR-Lex
Creative Commons Attribution 4.0 International (CC BY 4.0)
© European Union, https://eur-lex.europa.eu — Source: EUR-Lex (Publications Office of the European Union). Reused under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Only EU legislation published in the printed Official Journal of the European Union is deemed authentic; consolidated texts are reproduced here for documentation purposes and have been reformatted to Markdown.